Company Filing History:
3 out of 32 
3 out of 72 
1 out of 36 Years Active: 1995-2005
Title: The Innovations of George S. Eisenbarth
Introduction
George S. Eisenbarth is a prominent inventor based in Wellesley, MA (US). He has made significant contributions to the field of diabetes research, particularly in understanding and treating Type 1 diabetes. With a total of 8 patents, his work has paved the way for advancements in immunological assays and therapeutic methods.
Latest Patents
Eisenbarth's latest patents include groundbreaking discoveries related to Type 1 Diabetes Mellitus. One notable patent describes an antigen associated with the disease, specifically a 69 kD protein designated PM-1. This protein is expressed in human pancreatic islet cells and a human insulinoma. The amino acid sequence of PM-1 has been determined, and autoantibodies to this protein have been found in the sera of prediabetic patients. This discovery allows for the development of natural, synthetic, or recombinant forms of the PM-1 protein, which can be utilized in immunochemical assays to detect anti-PM-1 autoantibodies and identify patients at risk of developing diabetes. Another significant patent outlines a method for treating or preventing Type 1 diabetes through the oral administration of insulin. This method includes administering insulin or disease-suppressive fragments of insulin in oral or aerosol dosage forms.
Career Highlights
Throughout his career, Eisenbarth has worked with notable organizations such as Autoimmune Inc. and Joslin Diabetes Center, Inc. His research has significantly impacted the understanding and management of diabetes, contributing to both academic and clinical advancements.
Collaborations
Eisenbarth has collaborated with esteemed colleagues in the field, including Howard L. Weiner and David A. Hafler. These collaborations have further enriched his research and expanded the scope of his innovations.
Conclusion
George S. Eisenbarth's contributions to diabetes research through his patents and collaborations have made a lasting impact on the field. His work continues to inspire advancements in the treatment and understanding of Type 1 diabetes.